(MACK) Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

Will highlight innovative nanoliposomal platform for patients with metastatic breast cancer

CAMBRIDGE, Mass., Dec. 4, 2015  — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present on its innovative nanoliposomal platform for patients with metastatic breast cancer at the 2015 San Antonio Breast Cancer Symposium, December 8 – 12, 2015 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

The presentations include a trials-in-progress abstract for the MM-302 HERMIONE Phase 2 clinical trial and a trials-in-progress abstract for the Phase 1 clinical trial investigating potential predictive response markers for ONIVYDE™ (irinotecan liposome injection), also known as MM-398 or “nal-IRI.” MM-302 is a HER2 targeted liposomal encapsulation of doxorubicin.

Poster Sessions:

• HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1) (Abstract OT3-01-01)
  Ongoing Trials Poster Session 3, Ongoing Trials – HER2
  Presentation: Friday, December 11, 2015 (5:00 PM CT)
  Exhibit Hall A-B

• A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398) (Abstract OT3-02-14)
  Ongoing Trials Poster Session 3, Ongoing Trials – Chemotherapy
  Presentation: Friday, December 11, 2015 (5:00 PM CT)
  Exhibit Hall A-B

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack’s first commercial product, ONIVYDE™ (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack’s website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contacts:
Media Contact
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

Investor Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

(TGTX) Recaps Schedule of Data Presentations

Investor Reception to be Held on Monday December 7, 2015 from 7:45 pm – 9:00 pm ET at the Hyatt Regency Orlando With Presentations by Leading Clinical Investigators

ORLANDO, Fla., Dec. 04, 2015  — TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations for their lead compounds at the upcoming 57^th American Society of Hematology Annual Meeting (ASH), to be held December 5-8, 2015, at the Orange County Convention Center in Orlando, Florida.

Presentations on TG-1101 and TGR-1202 at the ASH meeting include the following:

Clinical Posters:

• Title: Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
  • Abstract Number: 1538
  • Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
  • Date and Time:  Saturday, December 5, 2015; 5:30 PM- 7:30 PM ET
  • Location: Orange County Convention Center, Hall A
  • Presenter: Matthew Lunning, DO
• Title: A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia
  • Abstract Number: 2942
  • Session: 642. CLL: Therapy, excluding Transplantation: Poster II
  • Date and Time:  Sunday, December 6, 2015; 6:00 PM-8:00 PM ET
  • Location: Orange County Convention Center, Hall A
  • Presenter: Daruka Mahadevan, MD, PhD
• Title: Ublituximab (TG-1101), A Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With Ibrutinib is Highly Active in Patients With Relapsed And/Or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
  • Abstract Number: 3980
  • Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
  • Date and Time:  Monday, December 7, 2015; 6:00 PM- 8:00 PM ET
  • Location: Orange County Convention Center, Hall A
  • Presenter: Kathryn Kolibaba, MD
• Title: TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma
  • Abstract Number: 4154
  • Session: 642. CLL: Therapy, excluding Transplantation: Poster III
  • Date and Time:  Monday, December 7, 2015; 6:00 PM- 8:00 PM ET
  • Location: Orange County Convention Center, Hall A
  • Presenter: Owen O’Connor, MD, PhD

Non-Clinical Oral Presentation:

• Title: Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas
  • Abstract Number: 593
  • Oral Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Novel Therapies and Targets in Lymphoma
  • Date and Time:  Monday, December 7, 2015; 10:30 AM – 12:00 PM ET
  • Presentation Time: 11:30 AM ET
  • Location: Orange County Convention Center, Tangerine 1 (WF1)
  • Presenter: Changchun Deng, MD, PhD

A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org.

TG Therapeutics will also host a reception on Monday, December 7^th, 2015 beginning at 7:45pm ET, with featured presentations beginning promptly at 8:00pm ET.  The event will take place at the Hyatt Regency Orlando in the Bayhill 17/18 Room.  This event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company’s website at www.tgtherapeutics.com, as well as archived for future review.   This event will also be broadcast via conference call.  In order to access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG Therapeutics 2015 Investor & Analyst Event.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303, will not prove to be a safe and efficacious backbone for triple and quad combination therapies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX-G

CONTACT: Jenna Bosco
Director- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com

(OPCO) Dean Tsengas Named Chief Operations Officer

(ENPH) Next-Gen AC Solar Modules Combine LG High-Efficiency Panels, Enphase Microinverters

LG Electronics (LG) and Enphase Energy, Inc. (NASDAQ:ENPH), have agreed to integrate Enphase’s microinverter technology into LG Electronics’ new generation of AC solar modules (ACM) for the global solar market.

The LG high-performance backsheet-integrated ACM will incorporate Enphase’s next-generation S-series microinverter with LG’s high-efficiency NeON 2 photovoltaic (PV) panels. Initial shipments of the LG-Enphase ACMs are expected to begin in the second half of 2016.

“Large solar distributors, installers and fleet owners want a reliable, low-cost, high-performance AC module product,” said Stefan Zschiegner, vice president of product management at Enphase. “Pairing LG’s NeON 2 modules with Enphase’s advanced S-series microinverters will create an ACM that works with our smart home energy solution. The LG-Enphase ACM will simplify the supply chain, reduce capital and labor costs, and shorten the design and installation process.”

“The factory integration of LG’s NeON 2 modules next year with the Enphase microinverter system is expected to provide the high level module quality and performance desired today by distributors and installers,” said Ellen Kim, senior vice president of energy solutions, LG Electronics USA. “With a single SKU for the module and inverter, simplified warranty process, and one-stop after-sales technical support, the LG-Enphase ACM also will offer asset management advantages.”

The LG-Enphase ACM collaboration brings together two solar industry pacesetters. LG has become a leading innovator in the high-power PV module sector, while Enphase has established itself as the top residential inverter and module-level power electronics company in the United States.

The LG NeON 2 is the latest addition to the company’s family of high-efficiency PV modules. Based on LG’s monocrystalline Cello technology, the 60-cell LG NeON 2 offers a peak output of up to 320 watts. The LG NeON 2 recently won the Intersolar Award 2015 for excellence in the PV module category.

The advanced, smart grid-ready Enphase S-Series Microinverter is designed to meet current and future requirements for distributed solar on utility networks, including the Rule 21 tariff in California. The fully bidirectional, software-defined microinverter system supports reactive power control and other advanced grid functionalities.

About LG Electronics USA

LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a $56 billion global force and technology leader in consumer electronics, home appliances and mobile communications. LG Electronics, a 2015 Energy Star Partner of the Year, sells a range of stylish and innovative home entertainment products, mobile phones, home appliances, commercial displays, air conditioning systems, LED lighting and solar energy solutions in the United States, all under LG’s “Life’s Good” marketing theme. For more information, please visit http://www.lg.com and http://www.lgsolarusa.com.

About Enphase

Enphase Energy, a global energy technology company, is leading the charge to bring smart, connected solar energy to every home, business and community. The company delivers simple, innovative and reliable energy management solutions that advance the worldwide potential of renewable energy. Enphase has shipped approximately 10 million microinverters, and more than 370,000 Enphase residential and commercial systems have been deployed in more than 95 countries. Join Enphase on LinkedIn and Twitter and visit www.enphase.com for more information.

Enphase Energy^®, the Enphase logo and other trademarks or service names are the trademarks of Enphase Energy, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to Enphase Energy’s financial performance, market demands for its products, advantages of its technology and market trends. These forward-looking statements are based on the company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks detailed in the “Risk Factors” and elsewhere in Enphase Energy’s latest Securities and Exchange Commission filings and reports. Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(YECO) Approval of Technical Code by Henan Authorities

Yulong Eco-Materials Limited (NasdaqCM:YECO), an eco-friendly building products and construction waste management company, today announced that the provincial technical code governing the use of recycled construction waste materials used in the production of roadbed – a road’s surface – was preliminarily approved by the Department of Transportation of Henan Province. This code was submitted by the Company in cooperation with the Henan Communication Science and Technology Research Institute, Ltd.

The Company expects to receive final approval for this technical code from the Henan Bureau of Quality and Technical Supervision before 2015 year-end, at which time it will become the standard code for the road construction industry in Henan.

As previously announced, this technical code provides improved parameters related to the type and amount of recycled construction waste used in the roadbed (the roadbed’s thickness, strength and other qualities affecting overall roadbed quality and safety).

Following the final approval, the Company’s recycled waste materials can be used in major road paving projects such as highways, expressways and other high quality road paving projects in Henan Province. Based on the amount of recycled construction waste expected to be generated by current projects, Yulong expects to sell more than two million cubic meters of recycled waste materials in fiscal 2016, at about $2.50 per cubic meter, thus generating approximately $5 million in revenue.

Mr. Yulong Zhu, Yulong’s CEO, noted, “Since the beginning of fiscal 2016, we have commenced several long-term, multi-million dollar construction waste management projects that should generate significant revenue from hauling, recycling, as well as the sale of recycled materials, for years to come. It is estimated that the demand for recycled construction materials by major highway contractors in Henan Province is over 10 million metric tons annually. Once the technical code is approved by the local authorities, we expect to start selling such recycled waste materials, and this segment of our business should grow substantially in the coming months. Total revenue generated from our construction waste management business is expected to represent over 25% of Yulong’s total revenue in fiscal 2016.”

About Yulong Eco-Materials
Yulong is a vertically integrated manufacturer of eco-friendly building products and a construction waste management company located in the city of Pingdingshan in Henan Province, China. The Company is currently Pingdingshan’s leading producer of fly-ash bricks and concrete as well as the exclusive provider of construction waste management services for the cities of Pingdindshan and Shangqiu.

Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Investor Relations Counsel:
The Equity Group Inc.
Lena Cati, 212-836-9611
Vice President
lcati@equityny.com
www.theequitygroup.com
or
Asia IR•PR
Jimmy Caplan, 512-329-9505
Managing Director
jimmy@asia-irpr.com
or
Media Relations:
Asia IR•PR
Rick Eisenberg, 212-496-6828
Managing Director
rick@asia-irpr.com

(UBIC) “Lit i View EMAIL AUDITOR” Adds Function to Spot Bribery in China

Helping Japanese Companies Operating in China Mitigate Legal Risks by Searching Business Emails for Indications of Bribery

TOKYO, Dec. 3, 2015  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today that it has launched a new function for its Lit i View EMAIL AUDITOR automated email audit system that is designed to detect email exchanges that may be indications of acts of bribery in China, which will assist UBIC’s clients in preventing violations of regulations that prohibit bribing foreign public officials, including the U.S. Foreign Corrupt Practices Act (FCPA).

The EMAIL AUDITOR identifies suspicious emails by using UBIC’s KIBIT artificial intelligence (AI) system to examine email texts and attached files transferred from clients’ in-house email systems. This system is capable of analyzing texts written in Japanese, English, Chinese and Korean and reduces the audit time of those texts by a factor of 500 to 1,000 when compared with the speed of a human audit. To date, UBIC has provided this system, which includes functions to detect information leakage and inappropriate business practices such as price fixing, and has provided more than approximately 8,000 users who are in Japan and abroad, including electronic communication device producers, auto-parts manufacturers, and transportation companies.

The new function, which allows corporate clients to discover indications of bribery within their Chinese operations, is based on the accumulation of knowledge and insight related to the detection of suspicious emails in Chinese and English. When companies adopt this function, after feeding teaching data concerning what kinds of email exchanges should be identified into the KIBIT system they will be able to immediately search for email exchanges that suggest that bribery may have taken place.

As business transactions have become borderless, governments around the world are cracking down on acts of bribery involving foreign public servants. In addition to the enforcement of the FCPA by the United States and the Bribery Act by the United Kingdom, there are also moves in other countries, including China, Japan and Russia, to strengthen anti-bribery regulations. In particular, under the FCPA, the U.S. Department of Justice has implicated many companies of bribing public officials in China. In one such case, a company accused of bribing Chinese government officials had to pay as much as USD135 million as a settlement. Companies expanding into China must be prepared to deal with such risks.

Meanwhile, discovering or preventing acts of bribery in China can be very difficult because of a shortage of audit personnel and the difficulty in detecting wrongdoing due to a company’s lack of local knowledge and language skills.

UBIC has developed this new function based on know-how about detecting acts of bribery accumulated through its international litigation support services. This includes the supply of EMAIL AUDITOR to foreign clients, as its attention focuses on China, where many Japanese companies are operating and where anti-bribery audit is required due to differences in cultural backgrounds and customs. UBIC now supports legal compliance with anti-bribery regulations by providing this function to Japanese and multinational companies doing business in China.

Clients who have already adopted EMAIL AUDITOR can add this function for an additional initial cost of JPY600,000. Users adopting EMAIL AUDITOR for the first time will be able to use this function after paying the standard initial cost.

KIBIT

KIBIT is an AI engine developed by UBIC. KIBIT is a word coined by combining “kibi,” a Japanese word meaning “subtlety,” and “bit,” the smallest unit of digital information, in order to indicate an AI capable of understanding the subtle elements of human behavior and personality.

About UBIC, Inc.

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) supports the analysis of big data based on behavior informatics by utilizing its technology, “KIBIT”. UBIC’s KIBIT technology is driven by UBIC AI based on knowledge acquired through its litigation support services. The KIBIT incorporates experts’ tacit knowledge, including their experiences and intuitions, and utilizes that knowledge for big data analysis. UBIC continues to expand its business operations by applying KIBIT to new fields such as healthcare and marketing.

UBIC was founded in 2003 as a provider of e-discovery and international litigation support services. These services include the preservation, investigation and analysis of evidence materials contained in electronic data, and computer forensic investigation. UBIC provides e-discovery and litigation support by making full use of its data analysis platform, “Lit i View®”, and its Predictive Coding technology adapted to Asian languages.

For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubic-global.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: UBIC Global PR
         UBIC North America, Inc.
         Tel: (212) 924-8242
         global_pr@ubic.co.jp

(MEET) Achieves Record-High Mobile DAU and MAU in November

MeetMe, Inc. (NASDAQ: MEET), a public market leader for social discovery, has set a new mobile monthly active user (MAU) record of 4,039,950 in November. This is the first time mobile MAU has exceeded four million in the company’s history, and represents a 27% increase in MAU year-over-year. The company also announced that during the month of November, average mobile daily active users (DAU) surpassed 1.1 million for the first time.

”We are thrilled to announce our new mobile MAU and average DAU records for November,” said Geoff Cook, CEO of MeetMe. “One of our stated goals is to continue to drive user engagement and the team has worked hard to execute on an ambitious product pipeline. We look forward to continuing to make MeetMe the best place to meet new people.”

About MeetMe, Inc.

MeetMe® is the leading social network for meeting new people in the US and the public market leader for social discovery (NASDAQ: MEET). MeetMe makes it easy to discover new people to chat with on mobile devices. With approximately 80 percent of traffic coming from mobile and more than one million total daily active users, MeetMe is fast becoming the social gathering place for the mobile generation. MeetMe is a leader in mobile monetization with a diverse revenue model comprising advertising, native advertising, virtual currency, and subscription. MeetMe apps are available on iPhone, iPad, Android, and Windows Phone in multiple languages, including English, Spanish, Portuguese, French, Italian, German, Chinese (Traditional and Simplified), Russian, Japanese, Dutch, Turkish and Korean. For more information, please visit meetmecorp.com.

Cautionary Note Concerning Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including future levels of MAU and DAU, whether we will continue to drive user engagement, whether we will execute on our product pipeline, and whether we will continue to make MeetMe the best place to meet new people. All statements other than statements of historical facts contained herein are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “project,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the risk that our applications will not function easily or otherwise as anticipated, the risk that we will not launch additional features and upgrades as anticipated, the risk that unanticipated events affect the functionality of our applications with popular mobile operating systems, any changes in such operating systems that degrade our mobile applications’ functionality and other unexpected issues which could adversely affect usage on mobile devices. Further information on our risk factors is contained in our filings with the Securities and Exchange Commission (“SEC”), including the Form 10-K for the year ended December 31, 2014 and the Current Report on Form 8-K filed with the SEC on June 3, 2015. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

(FOMX) Positive Top-Line Results From Phase II Study for FDX104

Conference Call and Webcast Today, December 3rd @ 8:30am Eastern Time

• FDX104 prevented the development of moderate-to-severe antibody-induced rash in the majority of cases.
• FDX104 appears safe and was well-tolerated.

REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 3, 2015  — Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced positive top-line results from its Phase 2 clinical study of FDX104 (a topical foam containing 4% doxycycline) in the prevention of moderate-to-severe skin rashes in patients treated with the epidermal growth factor receptor antibody inhibitors (EGFRI) cetuximab (Erbitux®, Eli Lilly) or panitumumab (Vectibix®, Amgen) for head and neck and colon cancers, among others. The results showed a statistically significant effect of FDX104 in reducing the severity of the antibody-induced rash.

The rash, also referred to as acneiform (acne-like) rash, is the most common side effect of EGFRI drugs, and can severely impact patients’ physical, psychological and social well-being, often leading to treatment discontinuation or dose reduction. According to the prescription information of cetuximab and panitumumab, in the event of a severe rash, the dosing of the EGFRI drug should be withheld, reduced or discontinued.^(1,2)

Twenty-four patients were enrolled and received study drug in a multicenter, randomized, double-blind, placebo-controlled, Phase 2 clinical study to evaluate the safety and efficacy of FDX104. Each patient acted as his or hers own control by treating one side of the face with FDX104 and the other side with the matching foam vehicle (Placebo) in a blinded and randomized manner. Photographs of the front and each side of the face were taken at each study visit; these photographs were used for blinded grading of rash severity by an independent dermatologist at the end of the study. The ratings of rash severity were: None=0, Mild=1, Moderate=2 and Severe=3, as described by Scope et al.⁽³⁾ The key findings were:

• In the entire study population (N=24) the severity of rash on the FDX104 treatment side of the face was overall better than in the Placebo-treated side.
• The mean Maximal rash severity (N=24) was 1.33 and 1.71 in the FDX104- and placebo-treated sides respectively.
• Nine of the 24 patients in the study (37.5%) developed severe (Grade 3) rash during the study on the placebo-treated side, while only 4 of the 24 patients in the study (16.7%) developed severe rash on the FDX104-treated side.
• Comparison of the two treatments on the prevention of severe rash reached statistical significance (p<0.05, Wilcoxon Signed-Rank test). Various other exploratory analyses trended similarly.
• FDX104 appears safe and well-tolerated. No drug-related systemic adverse events were recorded. Local reactions were noted in 6 patients, all were mild and 5 were resolved before the end of the study.

Severity was also assessed by the study investigators at each study visit using a modified MASCC EGFR Inhibitor Papulopustular Eruption Grading Scale (MESTT).⁽⁴⁾ The results showed overall similar trends, but were not statistically significant.

“Acneiform rash is the most noticeable side effect of EGFRI drugs. In many cases it is necessary to interrupt treatment to manage these side effects,” said Einat Shacham-Shmueli, MD, Head of Gastrointestinal Oncology Unit, Sheba Medical Center, Israel, who was a Principal Investigator in this study. “The ability of FDX104 to reduce the incidence and severity of such rash is impressive and promising. We currently don’t have an effective treatment for this side effect, which is especially disturbing and disruptive to this population,” she added.

“There is a significant unmet need for a safe and effective treatment for EGFRI-induced rash, and we are pleased with the results of this clinical study,” stated Dov Tamarkin, Ph.D., Foamix’s CEO. “FDX104 has the potential to improve patients’ quality of life and help maintain patients on their optimal anti-cancer treatment. We are dedicated to developing best-in-class medicines that can have a positive impact on patients’ lives.”

(1) Highlights of Prescribing Information for Erbitux®: http://pi.lilly.com/us/erbitux-uspi.pdf
(2) Highlights of Prescribing Information for Vectibix®: http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf
(3) Scope A, et al. J Clin Oncol 2007; 25 (34):5390–5396
(4) Lacouture MA et al. Support Care Cancer 2010; 18:509-522

About EGFRI-Induced Rash

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in a variety of solid tumors, including gastrointestinal (GI) tumors. Agents targeting the EGFR-mediated signaling pathway are increasingly part of the therapeutic means available for the treatment of advanced lung, head-and-neck, and colorectal carcinoma. The EGFR inhibitors (EGFRIs) approved in the United States include tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIs have been proven effective in the treatment of a variety of cancers, their most common side effects are severe acne-like rashes on the face and upper trunk, which occur in between 49%-95% of the patients.⁽⁵⁾ This toxicity results in significant physical and emotional patient stress, which in many cases necessitates changes in the oncological treatment.  While there are no approved treatments for EGFRI-induced rash, physicians have been treating patients off label with the oral minocycline and doxycycline, as well as various topical therapies to prevent and decrease the acne-like rash.^(5,6)  Although these treatments have shown benefit, they can have significant drawbacks, including systemic side effects and potential drug-drug interaction with the patients’ primary oncology treatment. Therefore, a more effective treatment is much sought after by oncologists.

(5) Grace K et al, CA: A Cancer Journal for Clinicians, 2013; 63 (4):249-279
(6) Lacouture M et al, Support Care Cancer, 2011; 19:1079–1095

About Foamix

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations. Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital. We discuss many of these risks in greater detail under the heading “Risk Factors” in our most recent Registration Statement on From F-1 (File No. 333-203187) declared effective on April 14, 2015, and elsewhere in that Registration Statement. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACT: Dorit Hayon
         Foamix Pharmaceuticals Ltd.
         +972-8-9316233
         BD@foamixpharma.com

         US Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6979
         mrice@lifesciadvisors.com

(DEST) Declares Quarterly Cash Dividend

MOORESTOWN, N.J., Dec. 3, 2015  — Destination Maternity Corporation (Nasdaq: DEST), the world’s leading maternity apparel retailer, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.20 per share.  The cash dividend will be payable January 21, 2016 to stockholders of record at the close of business on January 7, 2016.

Destination Maternity Corporation is the world’s largest designer and retailer of maternity apparel.  As of August 1, 2015 Destination Maternity operates 1,865 retail locations in the United States, Canada, Puerto Rico and, most recently, England, including 552 stores, predominantly under the trade names Motherhood Maternity®, A Pea in the Pod®, and Destination Maternity®, and 1,313 leased department locations.  In July 2015 the Company opened its first A Pea in the Pod branded leased department outside of North America in Harrods department store in London, England. The Company also sells merchandise on the web primarily through its motherhood.com, apeainthepod.com and destinationmaternity.com websites. Destination Maternity has international store franchise and product supply relationships in the Middle East, South Korea, Mexico and Israel. As of August 1, 2015 Destination Maternity has 148 international franchised locations, including 26 standalone stores operated under one of the Company’s nameplates and 122 shop-in-shop locations. Destination Maternity also distributes its Oh Baby by Motherhood® collection through a licensed arrangement at Kohl’s® stores throughout the United States and on Kohls.com.

The Company cautions that any forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) contained in this press release or made from time to time by management of the Company, including those regarding the continuation of the regular quarterly cash dividend, the trading liquidity of our common stock, potential stock repurchases, results of operations, liquidity and financial condition, and various business initiatives, involve risks and uncertainties, and are subject to change based on various important factors.  The following factors, among others, in some cases have affected and in the future could affect the Company’s financial performance and actual results and could cause actual results to differ materially from those expressed or implied in any such forward-looking statements: the continuation of the economic recovery of the retail industry in general and of apparel purchases in particular, our ability to successfully manage our various business initiatives, our ability to successfully pursue, complete and manage any acquisitions and related matters, adverse effects on the market price of our common stock and on our operating results because of a failure to complete any proposed acquisition, failure to realize any benefits of any  proposed acquisition, the success of our international business and its expansion, our ability to successfully manage and retain our leased department and licensed relationships and marketing partnerships, future sales trends in our existing retail locations and through the Internet, unusual weather patterns, changes in consumer spending patterns, raw material price increases, overall economic conditions and other factors affecting consumer confidence, demographics and other macroeconomic factors that may impact the level of spending for apparel, expense savings initiatives, our ability to anticipate and respond to fashion trends and consumer preferences, unanticipated fluctuations in our operating results, the impact of competition and fluctuations in the price, availability and quality of raw materials and contracted products, availability of suitable store locations, continued availability of capital and financing, our ability to hire and develop senior management and sales associates, our ability to develop and source merchandise, our ability to receive production from foreign sources on a timely basis, potential stock repurchases, our ability to continue our regular quarterly cash dividend, the trading liquidity of our common stock, changes in market interest rates, our ability to successfully manage and accomplish our planned relocations of our headquarters and distribution operations with minimal disruption to our overall operations, war or acts of terrorism and other factors set forth in the Company’s periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), or in materials incorporated therein by reference. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement. The Company assumes no obligation to update or revise the information contained in this announcement (whether as a result of new information, future events or otherwise), except as required by applicable law.

(LINC) Receives Military Friendly Schools Designation, 7th Consecutive Year

WEST ORANGE, N.J., Dec. 2, 2015  — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training, has been named to the 2016 list of Military Friendly Schools by Victory Media, the premier media entity for military personnel transitioning into civilian life.  The original Lincoln campus – Lincoln Technical Institute of Newark, NJ – was established in 1946 to assist returning World War II veterans, and Lincoln Tech schools are proud to carry on that tradition of service today.

“It’s a true honor to once again be recognized and designated a Military Friendly School,” says Scott Shaw, Lincoln’s President and CEO.  “The Lincoln tradition dates back to the end of World War II, because our founders wanted to be able to give back to the servicemen who had given so much to our nation.  We’ve never lost sight of that mission, and we place the highest emphasis on ensuring America’s veterans will always have a partner in Lincoln to assist them in adapting the skills they learned in the military for civilian careers.”

Lincoln Tech has received the Military Friendly Schools designation every year since Victory Media launched the initiative in 2009.  U.S. veterans are served by each of Lincoln’s 30 campuses around the nation.  While students train for professional skills that help launch civilian careers, they also work closely with Lincoln faculty to build academic skills, and with Career Services teams who help them network with a broad range of employer partners.  Lincoln helps veterans translate their military experience into tangible professional skills that hiring managers are looking for; each campus has detailed knowledge of which local employer partners are best suited for students rejoining the civilian workforce.

“Post-secondary institutions earning the 2016 Military Friendly School award have exceptionally strong programs for transitioning service members and spouses,” said Daniel Nichols, Chief Product Officer of Victory Media and Navy Reserve veteran. “Our Military Friendly Schools are truly aligning their military programs and services with employers to help students translate military experience, skills and training into successful careers after graduation.”

http://www.militaryfriendlyschools.com/methodology

Victory Media is the leader in successfully connecting the military and civilian worlds, and publishes G.I. Jobs®, STEM JobsSM and Military Spouse. Now in its seventh year, the original, premier Military Friendly Schools designation provides service members and their families with transparent, data-driven ratings about post-military education and career opportunities. Institutions competed for the elite Military Friendly School title by completing a survey of more than 100 questions covering categories such as military support on campus, graduation and employment outcomes, and military spouse policies.

Lincoln campuses maintain contacts with Veterans services and programs around the country, and frequently host career fairs, job training seminars, and other workshops dedicated specifically to the needs of returning servicemen and women.  In addition, Lincoln continues to seek out and establish new partnerships and programs around the country to bridge the skills gap between the abilities of the workforce and the needs of employers.

About Lincoln Educational Services Corporation

Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in five principal areas of study: automotive technology, health sciences, skilled trades, business and information technology, and hospitality services. Lincoln has provided the workforce with skilled technicians since its inception in 1946.

Lincoln currently operates 30 campuses in 15 states under four brands: Lincoln Technical Institute, Lincoln College of Technology, Euphoria Institute of Beauty Arts and Sciences, and Lincoln College of New England.  Lincoln also operates Lincoln Culinary Institutes in the states of Connecticut, Maryland and Florida.

For more information, go to lincolntech.edu.

Contact Information
Lincoln Educational Services Corporation
Peter Tahinos
(973) 736-9340 x49233
ptahinos@lincolntech.edu

(NVIV) Bioengineered Neural Trails™ Program for Chronic Spinal Cord Injury

InVivo Therapeutics Holdings Corp. (NVIV) today announced an innovative strategy for the treatment of chronic spinal cord injury (SCI). The company will focus its research efforts for chronic SCI on Bioengineered Neural Trails™. Bioengineered Neural Trails are injectable combinations of biomaterials and neural stem cells (NSCs) delivered using minimally-invasive surgical instrumentation and techniques to create trails across the chronic injury site. To support this strategy, InVivo has entered into agreements with the University of California, San Diego (UC San Diego) and James Guest, M.D., Ph.D., to expand the company’s intellectual property portfolio. InVivo entered into an exclusive license agreement with UC San Diego for issued patent US 9,011,410 titled “Spinal Multisegmental Cell and Drug Delivery System,” and into an assignment agreement with Dr. Guest for issued patent US 7,666,177 titled “Method and System for Cellular Transplantation in the Spinal Cord.” InVivo also has filed a provisional application in support of the Bioengineered Neural Trails program titled “Methods and Systems for Delivery of a Trail of a Therapeutic Substance.”

“Our goal is to restore neuronal connectivity and thereby promote neurological recovery in people with chronic SCI,” said Tom Ulich, M.D., Chief Scientific Officer of InVivo. “Our minimally-invasive therapeutic approach is to bridge the spinal cord lesion at the time of implantation with a trail of NSCs delivered in an injectable and biodegradable soft, gel-like scaffold. We look forward to presenting our preclinical results in the spinal cords of small and large animals during the Key Opinion Leader Event and Company Update on Thursday. ”

Mark Perrin, Chief Executive Officer and Chairman of InVivo, said, “We are excited about our novel Bioengineered Neural Trails program for the treatment of chronic spinal cord injury. The newly secured patents along with our provisional patent application provide the intellectual property foundation for our Bioengineered Neural Trails program.”

The company will discuss its innovative strategy for the treatment of chronic SCI during the KOL Event and Company Update webcast at 5:15PM ET on Thursday. The webcast will be broadly accessible through http://lifesci.rampard.com/20151203.

To learn more about our approach to chronic spinal cord injury, visit the InVivo Therapeutics website:
http://www.invivotherapeutics.com/research-clinical-development/pipeline/bioengineered-neural-trails/.

About Bioengineered Neural Trails™

Bioengineered Neural Trails are injectable combinations of biomaterials and neural stem cells (NSCs) delivered using minimally invasive surgical instrumentation and techniques to create trails across the chronic spinal cord injury site. InVivo’s Bioengineered Neural Trails program is currently being advanced preclinically by the Research and Development team at InVivo for the treatment of chronic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold™ received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the expected impact of the company’s Bioengineered Neural Trails program for the treatment of chronic SCI. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to execute on its development strategy and to obtain FDA approval for future clinical studies; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2014, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

(APDNW) Announces Closing of $8.75 Million Registered Direct Offering

(CCUR) Declares Quarterly Dividend

ATLANTA, Dec. 2, 2015  — Concurrent (NASDAQ: CCUR), a global provider of high‑performance Linux^® and storage solutions, today announced its Board of Directors has declared a quarterly cash dividend of $0.12 per share of common stock.  The dividend is payable on December 29, 2015 to shareholders of record at the close of business on December 15, 2015.

About Concurrent
Concurrent (NASDAQ: CCUR) is a global software and solutions company that develops advanced applications on a core foundation of high performance Linux and storage technologies. We serve industries and customers that demand uncompromising performance, reliability and flexibility to gain a competitive edge, drive meaningful growth and confidently deliver best-in-class solutions that enrich the lives of millions of people around the world every day.

Offices are located in North America, Europe and Asia. Visit www.concurrent.com for further information and follow us on Twitter: www.twitter.com/Concurrent_CCUR.

Certain statements made or incorporated by reference in this release may constitute “forward-looking statements” within the meaning of the federal securities laws. Statements regarding future events and developments and the company’s future performance, including, but not limited to, management’s expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. All forward-looking statements are subject to certain risks and uncertainties that could cause actual events to differ materially from those projected.

Other important risk factors are discussed in Concurrent’s Form 10-K filed August 26, 2015 with the Securities and Exchange Commission (“SEC”), and in subsequent filings of periodic reports with the SEC. The risk factors discussed in the Form 10-K and subsequently filed periodic reports under the heading “Risk Factors” are specifically incorporated by reference in this press release. Forward-looking statements are based on current expectations and speak only as of the date of such statements. Concurrent undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information, or otherwise.

Concurrent Computer Corporation and its logo are registered trademarks of Concurrent. All Concurrent product names are trademarks or registered trademarks of Concurrent while all other product names are trademarks or registered trademarks of their respective owners.

For more information, contact:

Media Relations:
Kristen Bryant
(678) 258-4221
kristen.bryant@ccur.com

Investor Relations:
ICR
Seth Potter
(646) 277-1230
Seth.Potter@icrinc.com

(NURO) to Participate in the Benchmark Micro Cap Discovery Conference

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the Benchmark Micro Cap Discovery One-On-One Conference at the Palmer House Hilton in Chicago, IL on Thursday, December 10, 2015 from 8:00am to 2:30pm. Dr. Gozani will meet with interested investors to discuss the Company’s business activities including the Quell^® Wearable Pain Relief device.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

(CTMX) to Present at Oppenheimer’s 26th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2015  — CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that it will present at Oppenheimer’s 26^th Annual Healthcare Conference in New York. Bob Goeltz, chief financial officer, and Rachel Humphrey, M.D., chief medical officer, will deliver a corporate overview at 9:10 a.m. EST on Tuesday, December 8.

A live audio webcast of the presentation will be available through the Investor and News page of CytomX’s website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics

CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Investigational Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1 against which our clinical candidate CX-072 is directed, as well as novel targets, such as CD-166, that are difficult to drug without causing damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc. MD Anderson Cancer Center, and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements. Our Probody platform is in preclinical development, and the process by which a preclinical technology could potentially lead to an approved product is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our preclinical research and development and other risks identified under the heading “Risk Factors” included in our filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

CONTACT: Media Contacts:
         Canale Communications
         Ian Stone
         ian@canalecomm.com
         619-849-5388

         Investor Contacts:
         Trout Group
         Pete Rahmer
         prahmer@troutgroup.com
         646-378-2973

(YECO) to Present at the LD Micro Investor Conference

Yulong Eco-Materials Limited (NasdaqCM:YECO), an eco-friendly building products and construction waste management company, today announced that its Chairman & Chief Executive Officer, Yulong Zhu and Chief Financial Officer, Zan Wu, will present at the LD MICRO Investor Conference at 10:00 am PT on December 3, 2015, at the Luxe Sunset Boulevard Hotel, in Los Angeles, CA.

Management will also be available for one-on-one meetings throughout the day. To arrange a meeting with management, please contact Lena Cati at lcati@equityny.com or your contact at LD Micro (www.ldmicro.com).

Investors will be able to download the PowerPoint Presentation via the Investor Relations section of Yulong’s website, www.yulongecomaterials.com.

About Yulong Eco-Materials

Yulong is a vertically integrated manufacturer of eco-friendly building products and a construction waste recycling company located in the city of Pingdingshan in Henan Province, China. The Company is currently Pingdingshan’s leading producer of fly-ash bricks and concrete as well as its exclusive provider of waste management services.

Investor Relations Counsel:
The Equity Group Inc.
Lena Cati, 212-836-9611
Vice President
lcati@equityny.com
www.theequitygroup.com
or
Asia IR•PR
Jimmy Caplan, 512-329-9505
Managing Director
jimmy@asia-irpr.com
or
Media Relations:
Asia IR•PR
Rick Eisenberg, 212-496-6828
Managing Director
rick@asia-irpr.com

(DHRM) Appoints Xiaoguang Shen to the Company’s Board of Directors

BEIJING, Dec. 1, 2015  — Dehaier Medical Systems Ltd. (Nasdaq: DHRM) (“Dehaier Medical” or the “Company”), which develops, markets and sells medical devices and wearable sleep respiratory products in China and international markets, today announced that it has appointed Xiaoguang Shen to the Company’s Board of Directors. Mr. Shen will replace Yunxiang (“Phil”) Fan and will serve his term until the meeting of the shareholders of the Registrant in 2015. Dehaier Medical’s Board will remain at five members, with three independent directors.

Mr. Yunxiang (“Phil”) Fan tendered his resignation as a director from the Board of Directors of Dehaier Medical Systems Limited (the “Registrant”), effective November 24, 2015. Mr. Fan’s resignation was not due to any disagreement with the Registrant.

Effective the same day, the Nominating Committee of the Registrant recommended, and the Board of Directors of the Registrant approved, the appointment of Mr. Xiaoguang Shen to the Registrant’s Board of Directors.

Mr. Ping Chen, Chief Executive Officer of Dehaier Medical, stated, “We are very pleased to welcome Xiaoguang to the Board. His experience will prove valuable as we continue to move forward in our development.”

“We would like to thank Phil for his service. He has been an effective and influential member of our Board. We wish him well in his future endeavors.”

Mr. Xiaoguang Shen, 42, will serve as a Class II member of the Board of Directors, will serve on the Nominating Committee, the Audit Committee and the Compensation Committee and will serve as the Chairman of the Compensation Committee until the annual meeting of the shareholders of the Registrant in 2015, at which time the shareholders will vote on whether Mr. Shen will serve as a Class II member of the Board for another term.

Mr. Shen has served as the general manager of the investment department of CP Pharmaceutical Group since 2003. Prior to joining CP Pharmaceutical Group, Mr. Shen provided sales services in several pharmaceutical companies since 1997, including Wyeth Pharmaceutical from 1998 to 2000. Mr. Shen earned his bachelor’s degrees from the department of Chinese medicine of Harbin University of Commerce in 1997 and his MBA degree from Central University of Finance and Economics in Beijing, China in 2013.

About Dehaier Medical Systems Ltd.

Dehaier Medical is an emerging leader in the development, marketing and sale of medical products, including medical devices and wearable sleep respiratory products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco (UK). Dehaier Medical’s technology is based on six patents and eleven software copyrights. More information may be found at http://www.dehaier.com.cn.

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Dehaier Medical Systems Limited
Janice Wang
+86 10-5166-0080 ext. 211
investors@dehaier.com.cn

(ISCO) Announces Launch Plans for New Nano-Compound Products

CARLSBAD, CA–(December 01, 2015) – International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season.

The initial launch of the Molecular Renewal SerumTM is expected in mid-December of 2015, when a retail version of the product will be available for purchase by US-based consumers through Lifeline’s website. Subsequent product launches will target the domestic professional sales market, which includes luxury spas, aestheticians, and medical offices, as well as luxury skincare markets in Europe and Asia.

The technology behind Molecular Renewal SerumTM was developed by ISCO’s R&D Team and the serum was formulated by a well-known cosmetic chemist. Independent third party testing demonstrated that the new skin care product containing the novel nano-compound showed significant (p<0.01) improvement in skin elasticity and decrease in skin roughness in all subjects 4 and 8 weeks after the start of the study. In addition, the compound-treated group outperformed not only the baseline, but also the Retinol treated group. No adverse events, such as skin irritation, which has been reported as a common side effect of Retinol treatment, were reported in the compound-treated group. In addition to the clinical study, the nano-compound was tested on normal human keratinocytes, fibroblasts and a 3D model of human skin. In all of these models the proprietary compound induced up to twice the production of elastin and collagen compared to Retinoic Acid (the active form of Retinol) with none of its toxic characteristics. This technology is the next step forward from the current product family, which has earned recognition from many industry professionals as well as retail customers.

Dr. Steven F. Weiner, M.D. Facial Plastic Surgeon, a pioneer in the field of minimally invasive cosmetic procedures, commented: “Our office has been using Lifeline Stem Cell Skin products for about 4 years. We have used it on freshly lasered and microneedled skin without complications and with improved healing times. All of our Infini patients have Lifeline applied and most continue to use it well after treatment because of the noted skin improvements it provides. It’s our best-selling growth factor product because of its higher concentrations of growth factors, streamlined product line and superior results.”

Since its inception in 2010 in California, Lifeline has experienced steady growth in sales and is currently generating operating income. With $2,6M in YTD revenue, Lifeline continues to follow its upward growth trend. Lifeline’s Q3 revenues equaled $924K, with Q4 revenues expected to surpass Q3.

Lifeline employs a highly experienced team of employees, along with top industry consulting talent in order to develop cutting edge line-up of products based on proprietary extract derived from ISCO’s pluripotent stem cells. The extract is manufactured by ISCO R&D team in cGMP compliant facilities and undergoes rigorous QC and independent clinical testing. Current product line includes the Daily Defensive Complex, Recovery Night Moisture Serum, Eye Firming Complex, Dual Action Exfoliator, and Brightening Cleanser. In addition to the Molecular Renewal Serum, in 2015 Lifeline introduced two new products — Refresh Polishing Gelée and Neck Firming Complex. In 2016 Lifeline plans to introduce several new products based on its proprietary extract and nano-compound technologies.